|
|
|
|
| LEADER |
01311nam a2200265 u 4500 |
| 001 |
EB002010960 |
| 003 |
EBX01000000000000001173859 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.)
|h Elektronische Ressource
|b indication: for the treatment of adult patients with moderately to severely active Crohn disease
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Vedolizumab (Entyvio)
|
| 246 |
3 |
1 |
|a Vedolizumab (Entyvio -- Takeda Canada Inc.)
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c January 2021, 2021
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK572478
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that vedolizumab subcutaneous (SC) be reimbursed for the treatment of adult patients with moderately to severely active Crohn disease, only if certain conditions are met
|